{"id":"d-serine-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"D-serine is an endogenous amino acid that functions as a neuromodulator in the central nervous system. It binds to the glycine-binding site on NMDA receptors, which are required for full receptor activation alongside glutamate. By increasing D-serine availability, the drug potentiates NMDA receptor signaling, which is thought to enhance synaptic plasticity and cognitive function, particularly in conditions characterized by hypofunction of this pathway.","oneSentence":"D-serine acts as a co-agonist at the N-methyl-D-aspartate (NMDA) receptor by binding to the glycine site, enhancing glutamatergic neurotransmission.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:26.272Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia (negative and cognitive symptoms)"},{"name":"Cognitive impairment associated with schizophrenia"}]},"trialDetails":[{"nctId":"NCT07263022","phase":"PHASE3","title":"Cognitive Strategies in Early Psychosis 2","status":"NOT_YET_RECRUITING","sponsor":"University of Minnesota","startDate":"2026-04-13","conditions":"Psychosis, Schizophrenia Disorder, Schizoaffective Disorder","enrollment":24},{"nctId":"NCT07079930","phase":"PHASE1","title":"Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers","status":"RECRUITING","sponsor":"Hadassah Medical Organization","startDate":"2025-12-11","conditions":"Healthy Volunteers","enrollment":10},{"nctId":"NCT07377032","phase":"PHASE3","title":"TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders","status":"RECRUITING","sponsor":"Meyer Children's Hospital IRCCS","startDate":"2025-08-29","conditions":"GRIN-related Disorders, GRIN1, GRIN2A","enrollment":40},{"nctId":"NCT02974010","phase":"PHASE2","title":"Sequential Therapy for the Treatment of Severe Bipolar Depression.","status":"COMPLETED","sponsor":"NeuroRx, Inc.","startDate":"2018-01-15","conditions":"Bipolar Depression, Suicidal Ideas, Suicidal Ideation","enrollment":22},{"nctId":"NCT04453371","phase":"PHASE3","title":"Impact of Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (COVID-19)","status":"WITHDRAWN","sponsor":"Negovsky Reanimatology Research Institute","startDate":"2020-10-15","conditions":"Acute Respiratory Distress Syndrome","enrollment":""},{"nctId":"NCT02014402","phase":"PHASE2","title":"Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Surgery","status":"COMPLETED","sponsor":"Instituto Grifols, S.A.","startDate":"2013-12","conditions":"Hemostasis","enrollment":181},{"nctId":"NCT01222117","phase":"PHASE2","title":"A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2010-12","conditions":"Acute Peripheral Arterial Occlusion","enrollment":174}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":55,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"D-serine solution","genericName":"D-serine solution","companyName":"University of Minnesota","companyId":"university-of-minnesota","modality":"Small molecule","firstApprovalDate":"","aiSummary":"D-serine acts as a co-agonist at the N-methyl-D-aspartate (NMDA) receptor by binding to the glycine site, enhancing glutamatergic neurotransmission. Used for Schizophrenia (negative and cognitive symptoms), Cognitive impairment associated with schizophrenia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}